GO:0050683 AF-1 domain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050683 (AF-1 domain binding) is a molecular function defined as binding to an AF-1 protein domain, a ligand-independent transactivation domain required for full transcriptional activity of nuclear receptors.
• AF-1 domain binding is central to nuclear receptor signaling, enabling coactivator recruitment and target gene activation even in the absence of ligand.
• Key proteins include estrogen receptor alpha (ESR1), androgen receptor (AR), glucocorticoid receptor (NR3C1), retinoic acid receptor alpha (RARA), and coactivators such as NCOA1, NCOA2, and DDX5/DDX17.
• AF-1 domain interactions are implicated in breast cancer, prostate cancer, and endocrine resistance, making them attractive therapeutic targets.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential to dissect AF-1 domain binding mechanisms and validate drug targets.
• EDITGENE provides end-to-end CRISPR services, including custom cell model generation and CRISPR library screening, to accelerate AF-1 domain binding research.
Description
The Gene Ontology (GO) term GO:0050683, AF-1 domain binding, describes the molecular function of selectively binding to an AF-1 protein domain. AF-1 is a ligand-independent transactivation domain found in nuclear receptors, and it is required for their full transcriptional activity. This binding event is a critical step in nuclear receptor signaling, allowing coactivator proteins to dock onto the receptor and initiate gene expression programs. Researchers study AF-1 domain binding to understand how steroid and orphan nuclear receptors regulate development, metabolism, and disease. The interaction between AF-1 and coactivators such as NCOA1 (SRC-1) and NCOA2 (GRIP1) is essential for transcriptional activation. Moreover, AF-1 domain binding can be modulated by phosphorylation and dimerization, adding layers of regulation. Given its role in hormone-dependent cancers, AF-1 domain binding is a high-priority target for therapeutic intervention. This article provides a comprehensive overview of the mechanisms, key genes, disease associations, and research methods for studying GO:0050683.
AF-1 domain binding At A Glance
| GO ID | GO:0050683 |
|---|---|
| GO term | AF-1 domain binding |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Binding to an AF-1 protein domain, a ligand-independent transactivation domain which is required for the full transcriptional activity of the receptor. |
| Major function | Mediates coactivator recruitment and transcriptional activation by nuclear receptors. |
| Related processes | Nuclear receptor signaling, transcription regulation, hormone response. |
| Key regulators | ESR1, AR, NR3C1, RARA, NCOA1, NCOA2, DDX5, DDX17. |
| Disease relevance | Breast cancer, prostate cancer, endocrine resistance, metabolic disorders. |
What Is GO:0050683?
AF-1 domain binding (GO:0050683) is a molecular function defined as the selective interaction with an AF-1 protein domain. The AF-1 domain is a ligand-independent transactivation domain that is required for the full transcriptional activity of nuclear receptors. This binding typically involves coactivator proteins or other regulatory factors that recognize the AF-1 domain, leading to enhanced transcription of target genes.
Why Is AF-1 domain binding Important in Cell Biology?
AF-1 domain binding is a fundamental molecular event in nuclear receptor biology, enabling ligand-independent transcriptional activation that drives cell proliferation, differentiation, and survival. Dysregulation of AF-1 domain interactions is linked to cancer progression and resistance to endocrine therapies. Understanding this binding function is therefore critical for developing novel therapeutics that target nuclear receptor signaling.
• Enables ligand-independent activation of estrogen receptor alpha (ERα), a key driver in breast cancer.
• Facilitates coactivator recruitment (e.g., NCOA1, NCOA2) to nuclear receptors, enhancing transcription.
• Modulates partial agonist activity of selective estrogen receptor modulators (SERMs).
• Involved in glucocorticoid receptor-mediated gene expression and anti-inflammatory responses.
• Regulates retinoic acid receptor alpha (RARA) activity via phosphorylation of AF-1.
• Contributes to orphan nuclear receptor NOR-1 transactivation and drug response.
• Plays a role in AP-1 pathway crosstalk with estrogen receptors.
• Serves as a potential biomarker for endocrine therapy resistance.
• Provides a target for small-molecule inhibitors of AF-1 interactions.
• Essential for understanding tissue-specific hormone responses.
Molecular Mechanism of AF-1 domain binding
Recognition of the AF-1 Domain by Coactivators
In simple terms: Coactivator proteins bind to the AF-1 domain of nuclear receptors to turn on genes.
The AF-1 domain is a ligand-independent transactivation domain located in the N-terminal region of nuclear receptors. Coactivators such as NCOA1 (SRC-1) and NCOA2 (GRIP1) directly bind to the AF-1 domain, often in concert with the AF-2 domain, to enhance transcriptional activity. This binding is essential for full receptor function and can occur even in the absence of hormone.
Role of Dimerization and Phosphorylation
In simple terms: Receptor dimerization and phosphorylation modify how AF-1 binding works.
Dimerization of the ligand-binding domain (LBD) is required for AF-1-mediated partial agonist activity of SERMs, as shown for estrogen receptor alpha. Additionally, phosphorylation of the AF-1 domain by cyclin-dependent kinase 7 (CDK7) enhances its interaction with coactivators, as demonstrated for retinoic acid receptor alpha.
Integration with AF-2 Domain and Ligand Binding
In simple terms: AF-1 and AF-2 domains cooperate to recruit coactivators.
The N-terminal AF-1 domain of ERα interacts directly with the C-terminal AF-2-holding ligand-binding domain to recruit coactivator proteins, forming a functional unit that drives transcription. This synergy allows the receptor to respond to both ligand-dependent and independent signals.
RNA-Binding Coactivators and AF-1 Function
In simple terms: Some coactivators are RNA-binding proteins that assist AF-1 in activating genes.
A subfamily of RNA-binding DEAD-box proteins, including DDX5 and DDX17, acts as estrogen receptor alpha coactivators through the N-terminal AF-1 domain, with the RNA coactivator SRA. This highlights the diverse molecular partners that engage AF-1.
Orphan Nuclear Receptors and AF-1 Binding
In simple terms: Even orphan receptors use AF-1 domains to recruit coactivators.
The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. This demonstrates that AF-1 domain binding is a general mechanism across the nuclear receptor superfamily.
Key Genes Involved in GO:0050683 AF-1 domain binding
The following genes and proteins are central to AF-1 domain binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ESR1 | Estrogen receptor alpha; contains AF-1 domain that binds coactivators | Breast cancer, endocrine resistance, SERM activity |
| AR | Androgen receptor; AF-1 domain mediates ligand-independent activation | Prostate cancer, androgen deprivation therapy resistance |
| NR3C1 | Glucocorticoid receptor; AF-1 domain involved in partial agonist activity | Inflammation, glucocorticoid resistance |
| RARA | Retinoic acid receptor alpha; AF-1 phosphorylation by CDK7 | Acute promyelocytic leukemia, differentiation therapy |
| NCOA1 | SRC-1 coactivator; binds AF-1 domain | Transcriptional regulation, cancer |
| NCOA2 | GRIP1 coactivator; interacts with AF-1 | Nuclear receptor signaling, cancer |
| DDX5 | RNA helicase; coactivator via AF-1 with SRA | Breast cancer, transcription |
| DDX17 | RNA helicase; coactivator via AF-1 with SRA | Breast cancer, transcription |
| NOR-1 | Orphan nuclear receptor; AF-1 mediates transactivation | Drug response, metabolism |
| CDK7 | Kinase that phosphorylates AF-1 domain | Transcription regulation, cancer |
| CCNH | Cyclin H; binds RARα AF-2 to direct CDK7 phosphorylation of AF-1 | Cell cycle, transcription |
| JUN | AP-1 transcription factor; crosstalk with ER pathways | Breast cancer, gene regulation |
| FOS | AP-1 component; interacts with ER signaling | Breast cancer, gene regulation |
| SP1 | Transcription factor; cooperates with ER AF-1 | Gene regulation |
| SRA | RNA coactivator; enhances AF-1 function | Breast cancer, transcription |
| NCOA3 | SRC-3 coactivator; may interact with AF-1 | Cancer, transcription |
| MED1 | Mediator subunit; links AF-1 to transcription machinery | Transcription regulation |
How Is AF-1 domain binding Regulated?
AF-1 domain binding is regulated by multiple mechanisms, including phosphorylation of the AF-1 domain by kinases such as CDK7, which enhances coactivator recruitment. Dimerization of the ligand-binding domain is required for AF-1-mediated partial agonist activity of SERMs. Additionally, the interaction between AF-1 and AF-2 domains within the receptor modulates coactivator binding. RNA coactivators like SRA can also influence AF-1 activity.
AF-1 domain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ESR1 | Breast cancer, endocrine resistance | Knockout of AF-1 domain in MCF-7 cells; point mutations in AF-1 |
| AR | Prostate cancer, castration resistance | Knock-in of AF-1 mutations in LNCaP cells |
| RARA | Acute promyelocytic leukemia | Point mutation of AF-1 phosphorylation sites in NB4 cells |
| NR3C1 | Glucocorticoid resistance, inflammation | Knockout of AF-1 domain in A549 cells |
| NOR-1 | Metabolic disorders, drug response | Overexpression of AF-1 domain in HEK293 cells |
AF-1 Domain Binding in Breast Cancer
Estrogen receptor alpha (ERα) AF-1 domain binding is a key driver of breast cancer cell proliferation. The AF-1 domain interacts with coactivators such as NCOA1 and NCOA2 to activate genes promoting tumor growth. Dysregulated AF-1 activity contributes to resistance to endocrine therapies like tamoxifen, making it a therapeutic target.
AF-1 Domain Binding in Prostate Cancer
Androgen receptor (AR) AF-1 domain binding mediates ligand-independent activation, which is implicated in castration-resistant prostate cancer. Targeting AF-1 interactions may overcome resistance to androgen deprivation therapy.
AF-1 Domain Binding in Leukemia
In acute promyelocytic leukemia, retinoic acid receptor alpha (RARA) AF-1 domain phosphorylation by CDK7 regulates its transcriptional activity, influencing differentiation therapy outcomes.
AF-1 Domain Binding in Metabolic and Inflammatory Diseases
Glucocorticoid receptor AF-1 domain binding is involved in partial agonist activity and anti-inflammatory responses, with implications for glucocorticoid resistance. Orphan receptor NOR-1 AF-1 domain binding affects drug response and metabolism.
From AF-1 domain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AF-1 domain binding drive ligand-independent transcription? | Knockout of AF-1 domain in ERα-positive breast cancer cells |
| How does AF-1 phosphorylation affect coactivator recruitment? | Point mutation of phosphorylation sites in RARα |
| Can AF-1 mutations alter SERM response? | Knock-in of AF-1 mutations in ERα |
| What is the interactome of AF-1 domain? | Tagged knock-in of AF-1 domain for proteomics |
| Does overexpression of AF-1 coactivators promote tumor growth? | Overexpression of NCOA1/NCOA2 in cancer cell lines |
| Can CRISPR screening identify novel AF-1 regulators? | Genome-wide CRISPR library screening in ERα-positive cells |
How to Study the AF-1 domain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Luciferase reporter assay | Transcriptional activation | AF-1 activity in response to ligands |
| Co-immunoprecipitation | Protein-protein interactions | AF-1-coactivator binding |
| GST pull-down | Direct binding | AF-1 domain interaction with NCOA1 |
| Western blot | Protein expression and phosphorylation | AF-1 phosphorylation status |
| CRISPR knockout | Gene function loss | AF-1 domain requirement in cancer cells |
| CRISPR point mutation | Specific amino acid changes | Phosphorylation site mutants |
| CRISPR knock-in | Tagged or mutant protein expression | AF-1 interactome studies |
| CRISPR library screening | Genome-wide gene function | Identify novel AF-1 regulators |
Transcriptional Reporter Assays
Luciferase reporter assays using AF-1-responsive promoters are standard to measure AF-1 domain binding activity and coactivator recruitment.
Co-Immunoprecipitation and Pull-Down Assays
Co-IP and GST pull-down assays detect direct interactions between AF-1 domain and coactivators such as NCOA1, NCOA2, and DDX5.
Phosphorylation Analysis
Western blotting with phospho-specific antibodies and kinase assays assess AF-1 domain phosphorylation by CDK7.
CRISPR-Based Genomic Editing
CRISPR knockout, point mutation, and knock-in models enable functional dissection of AF-1 domain binding in disease-relevant cell lines.
How CRISPR Can Be Used to Study GO:0050683 AF-1 domain binding
Knockout
CRISPR knockout of the AF-1 domain or its coactivators (e.g., NCOA1, NCOA2) can abolish ligand-independent transcription, revealing essential roles in cancer cell proliferation.
Point Mutation
Introducing point mutations in the AF-1 domain (e.g., phosphorylation sites) via CRISPR allows precise dissection of regulatory mechanisms, such as CDK7-mediated phosphorylation.
Knock-in
Knock-in of tagged AF-1 domains (e.g., FLAG, HA) enables proteomic and imaging studies to track AF-1 interactions in live cells.
Overexpression
Overexpression of AF-1 domain or its coactivators using CRISPR activation (CRISPRa) can model gain-of-function states observed in endocrine-resistant cancers.
How EDITGENE Supports AF-1 domain binding Research
Researchers studying AF-1 domain binding-related genes often need to determine whether a candidate gene is causally involved in transcriptional regulation, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of AF-1 domain interactions and their downstream effects.
Contact EDITGENE today to design your custom CRISPR model for AF-1 domain binding research.
Frequently Asked Questions About AF-1 domain binding
What is AF-1 domain binding?
AF-1 domain binding (GO:0050683) is a molecular function where a protein binds to the AF-1 transactivation domain of nuclear receptors, a ligand-independent domain required for full transcriptional activity.
What genes are involved in AF-1 domain binding?
Key genes include ESR1, AR, NR3C1, RARA, NCOA1, NCOA2, DDX5, DDX17, and NOR-1.
How does AF-1 domain binding regulate transcription?
It recruits coactivators such as NCOA1 and NCOA2 to nuclear receptors, enhancing target gene expression even without ligand.
What diseases are associated with AF-1 domain binding?
Breast cancer, prostate cancer, leukemia, and metabolic disorders are linked to dysregulated AF-1 domain interactions.
What is the role of phosphorylation in AF-1 domain binding?
Phosphorylation of the AF-1 domain by kinases like CDK7 enhances coactivator recruitment and transcriptional activity.
How can CRISPR be used to study AF-1 domain binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of AF-1 domain interactions in disease-relevant cells.
What methods measure AF-1 domain binding?
Luciferase reporter assays, co-immunoprecipitation, GST pull-down, and Western blotting are commonly used.
Is AF-1 domain binding ligand-dependent?
No, AF-1 is a ligand-independent transactivation domain, though its activity can be modulated by ligand-bound AF-2.
What coactivators bind to the AF-1 domain?
NCOA1 (SRC-1), NCOA2 (GRIP1), DDX5, DDX17, and SRA RNA are known to interact with AF-1.
How does AF-1 domain binding contribute to endocrine resistance?
AF-1-mediated ligand-independent activation of ERα and AR can drive tumor growth despite hormone deprivation therapy.
Conclusion
AF-1 domain binding (GO:0050683) is a critical molecular function in nuclear receptor signaling, enabling ligand-independent transcriptional activation through coactivator recruitment. Its dysregulation is implicated in cancer and metabolic diseases, making it a promising therapeutic target. Advances in CRISPR-based models and screening technologies are accelerating our understanding of AF-1 domain interactions. EDITGENE's comprehensive services empower researchers to dissect these mechanisms and translate findings into novel therapies.
References
- 1. Liu X et al.. 2024. The N-terminal activation function AF-1 domain of ERα interacts directly with the C-terminal AF-2-holding ligand-binding domain to recruit the coactivator proteins.. PLoS One 19(10):e0312276 PMID: 39432505
- 2. Arao Y et al.. 2019. Transactivation Function-1-Mediated Partial Agonist Activity of Selective Estrogen Receptor Modulator Requires Homo-Dimerization of the Estrogen Receptor α Ligand Binding Domain.. Int J Mol Sci 20(15) PMID: 31366023
- 3. Bour G et al.. 2005. Cyclin H binding to the RARalpha activation function (AF)-2 domain directs phosphorylation of the AF-1 domain by cyclin-dependent kinase 7.. Proc Natl Acad Sci U S A 102(46):16608-13 PMID: 16275922
- 4. Cho S et al.. 2005. Role of activation function domain-1, DNA binding, and coactivator GRIP1 in the expression of partial agonist activity of glucocorticoid receptor-antagonist complexes.. Biochemistry 44(9):3547-61 PMID: 15736964
- 5. Watanabe M et al.. 2001. A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA.. EMBO J 20(6):1341-52 PMID: 11250900
- 6. Wansa KD et al.. 2003. The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine.. J Biol Chem 278(27):24776-90 PMID: 12709428
- 7. Arao Y et al.. 2021. The physiological role of estrogen receptor functional domains.. Essays Biochem 65(6):867-875 PMID: 34028522
- 8. Kushner PJ et al.. 2000. Estrogen receptor pathways to AP-1.. J Steroid Biochem Mol Biol 74(5):311-7 PMID: 11162939
